{"id":11204,"date":"2017-04-17T00:00:00","date_gmt":"2017-04-17T00:00:00","guid":{"rendered":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-dr-aiman-shalabi-as-chief-medical-officer-to-accelerate-precision-immunotherapy-clinical-collaborations\/"},"modified":"2022-07-13T04:20:41","modified_gmt":"2022-07-13T04:20:41","slug":"cri-appoints-aiman-shalabi-chief-medical-officer","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer","title":{"rendered":"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations"},"content":{"rendered":"\n<p>The Cancer Research Institute (CRI), a nonprofit organization established in 1953 to advance biomedical research with the goal of developing lifesaving immunotherapies for all forms of cancer, announced today that it has appointed Aiman Shalabi, Pharm.D., MBA, BCOP, as the organization\u2019s chief medical officer. In the role, he will provide strategic direction and integrated oversight for CRI\u2019s cancer immunotherapy clinical trial program, the CRI Anna-Maria Kellen Clinical Accelerator. This new appointment reflects CRI\u2019s commitment to deliver clinical innovations and unlock cures for patients with all types of cancer.<\/p>\n\n\n\n<figure class=\"wp-block-image alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"250\" height=\"297\" src=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/Shalabi_Aiman-formal-250x297-1.jpg\" alt=\"\" class=\"wp-image-9534\"\/><\/figure>\n\n\n\n<p>Dr. Shalabi joins CRI with over 17 years\u2019 experience developing transformative medicines. Most recently he was vice president and head, Immuno-Oncology Global Medical Affairs at AstraZeneca where he served in leadership roles to develop an immunotherapy program from pre-clinical stage to FDA submission. He has also been part of the development of five new medicines, several of which are approved globally. Prior to his industry experience, Dr. Shalabi also managed a portfolio of oncology agents at the US National Cancer Institute, Cancer Therapy Evaluation Program (CTEP) and led the compassionate use program providing cancer patients with access to new medicines prior to regulatory approval.<\/p>\n\n\n\n<p>\u201cAiman is a pioneer in clinical collaborations in combination immunotherapy research and development, and through his role at MedImmune\/AstraZeneca, our first industry collaborator, he contributed significantly to the early growth of the CRI Anna-Maria Kellen Clinical Accelerator,\u201d said Jill O\u2019Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute. \u201cWe are pleased he will be joining forces with CRI as we grow our clinical enterprise with our academic and industry partners.\u201d<\/p>\n\n\n\n<p>The CRI Anna-Maria Kellen Clinical Accelerator is a unique industry-academia collaboration model designed to unlock the potential of combination cancer immunotherapies. Dr. Shalabi will oversee the program, working with a comprehensive set of nonprofit resources that includes a global network of more than sixty leading scientists, clinical trials management capabilities, venture philanthropy funding, along with operational, reagent access, and co-funding partnerships with more than twenty nonprofit and industry organizations.<\/p>\n\n\n\n<p>\u201cI am delighted to work with the Cancer Research Institute and look forward to growing and accelerating research collaborations for groundbreaking precision immunotherapy combinations,\u201d said Dr. Shalabi. \u201cThe most important inventions I have witnessed in my career resulted from collaborating with experts from academia. Having this opportunity to build on these experiences will help us achieve our common goal\u2014finding cures for patients with cancer.\u201d<\/p>\n\n\n\n\n\n<p><strong><u>About the Cancer Research Institute<\/u><\/strong><\/p>\n\n\n\n<p>The Cancer Research Institute (CRI), established in 1953, is the world\u2019s leading nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 26 members of the National Academy of Sciences,&nbsp;CRI&nbsp;has invested $336 million in support of research conducted by immunologists and tumor immunologists at the world\u2019s leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to&nbsp;<a href=\"https:\/\/www.cancerresearch.org\/\" target=\"_blank\" rel=\"noopener\">cancerresearch.org<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nonprofit Cancer Research Institute appoints pharmaceutical executive to lead its clinical research program<\/p>\n","protected":false},"featured_media":1770,"template":"","tags":[32,35],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-11204","cri_news","type-cri_news","status-publish","has-post-thumbnail","hentry","tag-clinical-trials","tag-combination-therapies"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations - Cancer Research Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"Nonprofit Cancer Research Institute appoints pharmaceutical executive to lead its clinical research program\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-13T04:20:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"250\" \/>\n\t<meta property=\"og:image:height\" content=\"165\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer\",\"url\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer\",\"name\":\"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg\",\"datePublished\":\"2017-04-17T00:00:00+00:00\",\"dateModified\":\"2022-07-13T04:20:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg\",\"width\":250,\"height\":165},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media Room Article\",\"item\":\"https:\/\/www.cancerresearch.org\/media-room\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations - Cancer Research Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer","og_locale":"es_ES","og_type":"article","og_title":"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations - Cancer Research Institute","og_description":"Nonprofit Cancer Research Institute appoints pharmaceutical executive to lead its clinical research program","og_url":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer","og_site_name":"Cancer Research Institute","article_modified_time":"2022-07-13T04:20:41+00:00","og_image":[{"width":250,"height":165,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer","url":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer","name":"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg","datePublished":"2017-04-17T00:00:00+00:00","dateModified":"2022-07-13T04:20:41+00:00","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/202583fb-3e8a-45d9-9b98-4483735f1f16.jpg","width":250,"height":165},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-appoints-aiman-shalabi-chief-medical-officer#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Media Room Article","item":"https:\/\/www.cancerresearch.org\/media-room"},{"@type":"ListItem","position":3,"name":"CRI Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news\/11204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/1770"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=11204"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=11204"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=11204"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=11204"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=11204"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=11204"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=11204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}